Table 4.
Characteristics of hepatitis C virus patients at liver transplantation before and after direct-acting antiviral introduction, according to indication to waiting list registration (decompensated liver disease or hepatocellular carcinoma) n (%)
|
dec-HCV |
HCV/HCC |
|||||
| Pre-DAA n = 91 | Post-DAA n = 51 | P value | Pre-DAA n = 89 | Post-DAA n = 58 | P value | |
| Gender (male) | 74 (81) | 40 (78.4) | ns | 77 (86.5) | 49 (84.5) | ns |
| Age (yr) | 54.8 ± 8 | 56 ± 8 | ns | 57 ± 7 | 58 ± 7 | ns |
| Refractory ascites (yes) | 37 (40.6) | 27 (53) | ns | - | - | |
| Blood group | ns | ns | ||||
| 0 | 41 (45) | 21 (41.7) | 37 (41.5) | 19 (32.7) | ||
| A | 35 (38) | 22 (43.3) | 39 (43.8) | 28 (54.9) | ||
| AB | 3 (3.3) | 3 (5.8) | 4 (4.5) | 2 (3.4) | ||
| B | 12 (13) | 5 (9.8) | 9 (10.2) | 9 (15.5) | ||
| HCC (yes) | 19 (20.8) | 19 (37.3) | 0.04 | - | - | |
| Child-Pugh classes | ns | 0.001 | ||||
| A | 3 (3.2) | 1 (1.9) | 38 (42.6) | 42 (72.4) | ||
| B | 27 (29.6) | 17 (33.3) | 42 (47.2) | 12 (20.6) | ||
| C | 61 (67.1) | 33 (64.7) | 9 (10) | 4 (6.8) | ||
| MELD at LT | 24 ± 6.5 | 23 ± 7.5 | ns | 11.7 ± 4 | 11.2 ± 3 | ns |
| SVR at time of LT (yes) | 8 (8.8) | 15 (29.4) | 0.002 | 10 (11) | 24 (41) | 0.0001 |
| SVR after IFN-based regimens | 7 (7.6) | 2 (3.9) | 9 (10.1) | 1 (1.7) | ||
| Waiting time (mo) | 8.3 ± 12 | 10.6 ± 12 | ns | 9 ± 7.7 | 10 ± 11 | ns |
HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma; DAA: Direct-acting antivirals; BMI: Body mass index; MELD: Model of End-Stage Liver Disease; LT: Liver transplantation; SVR: Sustained virological response.